LAVA Therapeutics NV Profit Margin

The latest profit margin for LVTX is -466.43% as of September 2025. That compares with -365.02% in the prior-year period — down 27.8% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside LAVA Therapeutics NV's historical trend and sector peers before judging valuation or financial health.

Over the past year, LVTX's profit margin moved from -365.02% to -466.43% — a 27.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LAVA Therapeutics NV's valuation or profitability profile.

Against Healthcare companies, LVTX currently prints -466.43% for profit margin, while the sector average sits near 14.41%. That is roughly 3335.8% below the sector mean. Large gaps often invite a closer look at LAVA Therapeutics NV's growth, margins, and balance sheet.

Profit Margin shows how effectively LAVA Therapeutics NV converts resources into returns. At -466.43%, LVTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -365.02% in the prior-year period — down 27.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LVTX's profit margin (-466.43%), review year-over-year change from -365.02%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.